RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into a Securities Purchase Agreement with private investors on March 29, 2024. The agreement involves the issuance and sale of 2,144,487 American Depositary Shares (ADSs) and warrants to purchase an equivalent number of ADSs. Each ADS represents 400 ordinary shares of RedHill, with the purchase price set at $0.58289 per ADS and accompanying warrant. The warrants are exercisable at $0.75 per ADS and are valid for five years from the issuance date. The offering is expected to close on April 3, 2024, subject to customary closing conditions, and aims to raise gross proceeds of $1.25 million before offering expenses. This offering is part of a 'shelf' registration statement filed with the SEC on July 29, 2021, and declared effective on August 9, 2021. No placement agent was involved in the offering. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on their website.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into a Securities Purchase Agreement with private investors on March 29, 2024. The agreement involves the issuance and sale of 2,144,487 American Depositary Shares (ADSs) and warrants to purchase an equivalent number of ADSs. Each ADS represents 400 ordinary shares of RedHill, with the purchase price set at $0.58289 per ADS and accompanying warrant. The warrants are exercisable at $0.75 per ADS and are valid for five years from the issuance date. The offering is expected to close on April 3, 2024, subject to customary closing conditions, and aims to raise gross proceeds of $1.25 million before offering expenses. This offering is part of a 'shelf' registration statement filed with the SEC on July 29, 2021, and declared effective on August 9, 2021. No placement agent was involved in the offering. The final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on their website.